Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-INN805 in Advanced Malignant Solid Tumors
NCT07459283Phase 1Recruiting
- Sponsor
- FindCure Biosciences
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 177Lu-INN805 in malignant solid tumor, head and neck cancer (HNC), thyroid cancer and 3 more, sponsored by FindCure Biosciences. Primary endpoints: Dose-Limiting Toxicity at 42 days, Adverse Events and Serious Adverse Events at 12 months and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
177Lu-INN805
03
Conditions
malignant solid tumorhead and neck cancer (HNC)thyroid cancernon-small cell lung cancer (NSCLC)breast cancer
Beyond the preview
Go deeper on NCT07459283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07459283.